These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 28130143)

  • 1. Treatment-limiting renal tubulopathy in patients treated with tenofovir disoproxil fumarate.
    Hamzah L; Jose S; Booth JW; Hegazi A; Rayment M; Bailey A; Williams DI; Hendry BM; Hay P; Jones R; Levy JB; Chadwick DR; Johnson M; Sabin CA; Post FA
    J Infect; 2017 May; 74(5):492-500. PubMed ID: 28130143
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Kidney dysfunction associated with tenofovir exposure in human immunodeficiency virus-1-infected Taiwanese patients.
    Huang YS; Chan CK; Tsai MS; Lee KY; Lin SW; Chang SY; Hung CC; Chang SC
    J Microbiol Immunol Infect; 2017 Oct; 50(5):595-603. PubMed ID: 26514942
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Tenofovir Disoproxil Fumarate on Incidence of Chronic Kidney Disease and Rate of Estimated Glomerular Filtration Rate Decrement in HIV-1-Infected Treatment-Naïve Asian Patients: Results from 12-Year Observational Cohort.
    Suzuki S; Nishijima T; Kawasaki Y; Kurosawa T; Mutoh Y; Kikuchi Y; Gatanaga H; Oka S
    AIDS Patient Care STDS; 2017 Mar; 31(3):105-112. PubMed ID: 28282247
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estimated glomerular filtration rate slopes on tenofovir alafenamide.
    Ibrahim F; Campbell L; Bailey AC; Stockwell S; Waters L; Orkin C; Johnson M; Gompels M; De Burgh-Thomas A; Jones R; Schembri G; Mallon PW; Post FA
    HIV Med; 2020 Oct; 21(9):607-612. PubMed ID: 33021067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety of Tenofovir Alafenamide in People With HIV Who Experienced Proximal Renal Tubulopathy on Tenofovir Disoproxil Fumarate.
    Campbell L; Barbini B; Burling K; Cromarty B; Hamzah L; Johnson M; Jones R; Samarawickrama A; Williams D; Winston A; Post FA;
    J Acquir Immune Defic Syndr; 2021 Oct; 88(2):214-219. PubMed ID: 34506361
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renal function in Ethiopian HIV-positive adults on antiretroviral treatment with and without tenofovir.
    Yilma D; Abdissa A; Kæstel P; Tesfaye M; Olsen MF; Girma T; Ritz C; Friis H; Andersen ÅB; Kirk O
    BMC Infect Dis; 2020 Aug; 20(1):582. PubMed ID: 32762646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is Abnormal Urine Protein/Osmolality Ratio Associated with Abnormal Renal Function in Patients Receiving Tenofovir Disoproxil Fumarate?
    Marcelin JR; Berg ML; Tan EM; Amer H; Cummins NW; Rizza SA
    PLoS One; 2016; 11(2):e0149562. PubMed ID: 26872144
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of a tenofovir disoproxil fumarate plus ritonavir-boosted protease inhibitor-based regimen on renal function in HIV-infected individuals: a prospective, multicenter study.
    Cao Y; Han Y; Xie J; Cui Q; Zhang L; Li Y; Li Y; Song X; Zhu T; Li T
    BMC Infect Dis; 2013 Jul; 13():301. PubMed ID: 23815472
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estimated Glomerular Filtration Rate Trajectories in HIV-Infected Subjects Treated With Different Ritonavir-Boosted Protease Inhibitors and Tenofovir Disoproxil Fumarate or Abacavir.
    Gianotti N; Galli L; Poli A; Salpietro S; Nozza S; Carbone A; Merli M; Ripa M; Lazzarin A; Castagna A
    Medicine (Baltimore); 2016 May; 95(22):e3780. PubMed ID: 27258510
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fanconi syndrome accompanied by renal function decline with tenofovir disoproxil fumarate: a prospective, case-control study of predictors and resolution in HIV-infected patients.
    Gupta SK; Anderson AM; Ebrahimi R; Fralich T; Graham H; Scharen-Guivel V; Flaherty JF; Fortin C; Kalayjian RC; Rachlis A; Wyatt CM
    PLoS One; 2014; 9(3):e92717. PubMed ID: 24651857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incomplete reversibility of estimated glomerular filtration rate decline following tenofovir disoproxil fumarate exposure.
    Jose S; Hamzah L; Campbell LJ; Hill T; Fisher M; Leen C; Gilson R; Walsh J; Nelson M; Hay P; Johnson M; Chadwick D; Nitsch D; Jones R; Sabin CA; Post FA;
    J Infect Dis; 2014 Aug; 210(3):363-73. PubMed ID: 24585896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence and risk factors for tenofovir-associated renal toxicity in HIV-infected patients.
    Quesada PR; Esteban LL; García JR; Sánchez RV; García TM; Alonso-Vega GG; Ferrández JS
    Int J Clin Pharm; 2015 Oct; 37(5):865-72. PubMed ID: 26008219
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renal Dysfunction during Tenofovir Use in a Regional Cohort of HIV-Infected Individuals in the Asia-Pacific.
    Tanuma J; Jiamsakul A; Makane A; Avihingsanon A; Ng OT; Kiertiburanakul S; Chaiwarith R; Kumarasamy N; Nguyen KV; Pham TT; Lee MP; Ditangco R; Merati TP; Choi JY; Wong WW; Kamarulzaman A; Yunihastuti E; Sim BL; Ratanasuwan W; Kantipong P; Zhang F; Mustafa M; Saphonn V; Pujari S; Sohn AH;
    PLoS One; 2016; 11(8):e0161562. PubMed ID: 27560968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renal function with use of a tenofovir-containing initial antiretroviral regimen.
    Gallant JE; Moore RD
    AIDS; 2009 Sep; 23(15):1971-5. PubMed ID: 19696652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renal health after long-term exposure to tenofovir disoproxil fumarate (TDF) in HIV/HBV positive adults in Ghana.
    Villa G; Phillips RO; Smith C; Stockdale AJ; Beloukas A; Appiah LT; Chadwick D; Ruggiero A; Sarfo FS; Post F; Geretti AM
    J Infect; 2018 Jun; 76(6):515-521. PubMed ID: 29702139
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of long-term exposure to tenofovir disoproxil fumarate-containing antiretroviral therapy on renal function in HIV-positive Chinese patients.
    Tan Q; He YH; Yang TT; Yan DM; Wang Y; Zhao X; Liu HX; He SH; Zhou ZH
    J Microbiol Immunol Infect; 2019 Oct; 52(5):710-719. PubMed ID: 31427111
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low Risk of Proximal Tubular Dysfunction Associated With Emtricitabine-Tenofovir Disoproxil Fumarate Preexposure Prophylaxis in Men and Women.
    Mugwanya K; Baeten J; Celum C; Donnell D; Nickolas T; Mugo N; Branch A; Tappero J; Kiarie J; Ronald A; Yin M; Wyatt C;
    J Infect Dis; 2016 Oct; 214(7):1050-7. PubMed ID: 27029778
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early safety of tenofovir alafenamide in patients with a history of tubulopathy on tenofovir disoproxil fumarate: a randomized controlled clinical trial.
    Hamzah L; Williams D; Bailey AC; Jones R; Ibrahim F; Musso CG; Burling K; Barbini B; Campbell L; Post FA;
    HIV Med; 2020 Mar; 21(3):198-203. PubMed ID: 31679186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence of renal Fanconi syndrome in patients taking antiretroviral therapy including tenofovir disoproxil fumarate.
    Medland NA; Chow EP; Walker RG; Chen M; Read TR; Fairley CK
    Int J STD AIDS; 2018 Mar; 29(3):227-236. PubMed ID: 28764611
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study.
    Mocroft A; Lundgren JD; Ross M; Fux CA; Reiss P; Moranne O; Morlat P; Monforte Ad; Kirk O; Ryom L;
    Lancet HIV; 2016 Jan; 3(1):e23-32. PubMed ID: 26762990
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.